ULTRAGENYX PHARMACEUTICAL INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $13.20 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-27.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2020-10-27
- ULTRAGENYX PHARMACEUTICAL INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $9.73M.
- ULTRAGENYX PHARMACEUTICAL INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was -$3.94M, a 129.73% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $7.40M, a 10.66% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $346.00K.
- ULTRAGENYX PHARMACEUTICAL INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $21.86M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2020-09-30 | $9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $5.80M derived: sum of 2 quarters · filed 2020-10-27 | $13.20M 10-Q · filed 2020-10-27 | $13.54M derived: sum of 4 quarters · filed 2020-10-27 |
| 2020-06-30 | -$3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $3.46M 10-Q · filed 2020-07-30 | $3.81M derived: sum of 3 quarters · filed 2020-07-30 | $3.81M derived: sum of 4 quarters · filed 2020-10-27 |
| 2020-03-31 | $7.40M 10-Q · filed 2020-05-07 | $7.74M derived: sum of 2 quarters · filed 2020-05-07 | $7.74M derived: sum of 3 quarters · filed 2020-10-27 | $20.98M derived: sum of 4 quarters · filed 2020-10-27 |
| 2019-12-31 | $346.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $346.00K derived: sum of 2 quarters · filed 2020-10-27 | $13.58M derived: sum of 3 quarters · filed 2020-10-27 | $21.86M 10-K · filed 2020-02-14 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $13.23M derived: sum of 2 quarters · filed 2020-10-27 | $21.52M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $13.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $21.52M 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $8.28M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |